GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioxytran Inc (OTCPK:BIXT) » Definitions » Cash-to-Debt

Bioxytran (Bioxytran) Cash-to-Debt : 0.01 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Bioxytran Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Bioxytran's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.01.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Bioxytran couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Bioxytran's Cash-to-Debt or its related term are showing as below:

BIXT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0   Med: 0.07   Max: No Debt
Current: 0.01

During the past 13 years, Bioxytran's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.07.

BIXT's Cash-to-Debt is ranked worse than
99.16% of 1540 companies
in the Biotechnology industry
Industry Median: 6.485 vs BIXT: 0.01

Bioxytran Cash-to-Debt Historical Data

The historical data trend for Bioxytran's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Bioxytran Cash-to-Debt Chart

Bioxytran Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.03 0.03 0.14 0.01

Bioxytran Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.02 0.04 0.01 0.01

Competitive Comparison of Bioxytran's Cash-to-Debt

For the Biotechnology subindustry, Bioxytran's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioxytran's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioxytran's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Bioxytran's Cash-to-Debt falls into.



Bioxytran Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Bioxytran's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Bioxytran's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioxytran  (OTCPK:BIXT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Bioxytran Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Bioxytran's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioxytran (Bioxytran) Business Description

Traded in Other Exchanges
N/A
Address
75 2nd Avenue, Suite 605, Needham, MA, USA, 02494
Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. Its other drug candidate BXT-252 is a resuscitative agent in a variety of wound healing applications.
Executives
Dale H Conaway director 189 WELLS AVE, NEWTON MA 02459
Alan M Hoberman director 6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Anders Utter director BIOXYTRAN, INC, 233 NEEDHAM ST., SUITE 300, NEWTON MA 02464
David Platt director, 10 percent owner, officer: CEO 12 APPLETON CIRCLE, NEWTON MA 02459
Hana Chen-walden director 7 RUE ARISTIDE MAILLOL, PARIS I0 75015
Michael Sheikh officer: Chief Communication Officer 1905 S AUDUBON CT, SPOKANE WA 99224
Binder Offer other: No longer 10% owner PASQUALE VIA SETTEMBRIMI 14A, SAN MARIANO 06073, CORCIANO PG ITALY L6 00000
Ola Soderquist 10 percent owner, officer: CFO 47 HAMMOND STREET, UNIT 2, WALTHAM MA 02451
Lawrence W. Bonafide director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Nathan Marks director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Dave Quincy Farber director, officer: President 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
David Lee director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Donita R. Kendig director, officer: Secretary/Treasurer 78365 HWY 11, SUITE 287, LA QUINTA CA 92253
Afcc, Llc 10 percent owner 1621 CENTRAL AVENUE, CHEYENNE WY 82001
Paul W Hai 10 percent owner 20443 TIMBERLINE, BEND OR 97701